Metabolite Identification and Profiling

With more than 20 years of ADME expertise, our scientists go beyond metabolite detection to deliver scientifically meaningful interpretation of drug metabolism across the drug development process. From early in vitro metabolism through non-clinical ADME and human pharmacology studies, we establish a connection between what is formed in vitro, what is observed in animal species, and what ultimately occurs in humans.

Celerion Zurich metabolite identification laboratory

Connecting in vitro metabolism to human relevance

At our Zurich, Switzerland location, experienced MetID scientists combine high-resolution mass spectrometry with deep expertise in drug metabolism and ADME to identify, characterize, and interpret drug-related material across a broad range of biological matrices, including plasma, urine, feces, tissues, cells, and sub-cellular fractions.

Our MetID and metabolite profiling capabilities include:

In vitro cross-species metabolism and metabolite identification using hepatocytes, liver microsomes, and S9 fractions
Metabolite profiling and identification from radiolabelled animal and human ADME studies
Metabolite identification in animal and human matrices following administration of unlabelled test compounds
Cross-species and in vitro-to-in vivo metabolite comparisons to assess metabolite coverage and human relevance
High-resolution MS-based metabolite profiling and structural characterization to support confident metabolite identification from data to scientific insight

Our experienced scientists integrate analytical findings with ADME, pharmacology, exposure, and metabolic pathway knowledge to build a coherent understanding of drug metabolism. By connecting in vitro findings with animal and human data, we help identify relevant metabolites, assess species differences, and support scientifically informed decisions throughout drug development.

Analytical support for Celerion’s clinical pharmacology studies

Analysis of samples for human mass balance studies as part of clinical pharmacology are supported out of our Lincoln, Nebraska laboratory. Here, our ADME scientists are co-located with the clinical facility to support real-time scintillation counting for radioactivity recovery. Services include:

Dosimetry calculations and preparation of the human dosimetry report
Protocol review/comments and general consultation on ADME design
Verification of dosing solution radioactivity prior to administration to participants
Radioactive content measured in plasma, whole blood, and red blood cells; recovery measured from urine and feces
Daily real-time mass balance results
Collection of required aliquots for metabolite profiling